Core Insights - The company, Ascentage Pharma-B (06855), announced multiple clinical and preclinical advancements for three products (Orebactin®, Lisatoclax®, APG-5918) selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting, including one oral presentation [1] - Orebactin® has been selected for ASH for eight consecutive years, showcasing its ongoing clinical progress [1] - Lisatoclax® has two clinical advancements selected for ASH, marking its fourth consecutive year of inclusion [1] Group 1: Product Developments - Orebactin® is the first approved third-generation BCR-ABL inhibitor in China, with commercialization jointly managed by Ascentage Pharma and Innovent Biologics [2] - At the ASH meeting, the company will present the latest data from the global Phase III POLARIS-1 study on Orebactin® combined with low-intensity chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients [2] - The company will also update data from a randomized controlled Phase II study on Orebactin® for TKI-resistant chronic myeloid leukemia in chronic phase (CML-CP) patients, including four-year follow-up data [2] Group 2: Lisatoclax® Insights - Lisatoclax® is a novel oral Bcl-2 selective inhibitor developed by Ascentage Pharma, showing potential in treating various hematological malignancies and solid tumors [2] - The product has been approved in China for adult chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients who have undergone at least one systemic treatment, including a Bruton tyrosine kinase (BTK) inhibitor [2] - The company will present the latest advancements from a registered Phase II clinical study of Lisatoclax® as a monotherapy for relapsed/refractory CLL/SLL patients, along with data on its combination with azacitidine for newly diagnosed or previously venetoclax-treated myeloid tumor patients [2] Group 3: ASH Annual Meeting - The ASH Annual Meeting is one of the largest international academic events in the field of hematology, covering research on the etiology and treatment of blood diseases [3] - The 67th ASH Annual Meeting will take place from December 6 to December 9, 2025, in Orlando, Florida, in a hybrid format [3]
亚盛医药-B(06855)耐立克®、利生妥®、APG-5918的多项临床进展将在2025年美国血液学会年会(ASH)展示，其中一项获口头报告